1. Acalabrutinib With Obinutuzumab in Treatment‐Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3‐Year Follow‐Up. (12th June 2019) Authors: Woyach, J.; Rogers, K.A.; Bhat, S.; Blachly, J.; Jianfar, M.; Hamdy, A.; Frigault, M.M.; Izumi, R.; Munugalavadla, V.; Quah, C.S.; Wang, M.H.; Byrd, J.C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH‐RISK NON‐HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS. (12th June 2019) Authors: Maakaron, J.; Zhao, Q.; Puto, M.; Von Derau, R.; Robinson, J.; Brammer, J.; Penza, S.; Baiocchi, R.; Christian, B.; Maddocks, K.; Saad, A.; Wall, S.; Benson, D.; Efebera, Y.; Rosko, A.; Ayyappan, S.; Grieselhuber, N.; Vasu, S.; Larkin, K.; Epperla, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗